Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer
Authors:
- Noha H IbrahimNINoha H Ibrahim
- Mona S AbdellateifMAMona S Abdellateif
- Dina S SeragDSDina S Serag
- Ahmed LaymounaALAhmed Laymouna
- Mennatallah S ElaguizyMEMennatallah S Elaguizy
- Radwa Marawan Abdel HalimRHRadwa Marawan Abdel Halim
Open Access
- 20 September 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Experimental Medicine
- Vol. 15 (3)
Abstract
BACKGROUND Ovarian cancer (OC) is the most lethal gynecological cancer among females, and its early diagnosis could help for better outcomes of the patients. AIM To investigate the utility of serum insulin-like growth factors-binding proteins 2 (IGFBP2), secreted phosphoprotein 1 (SPP1), thrombospondin 1 protein (TSP1) and D-dimer levels in addition to currently used biomarkers [cancer antigen 125 (CA125) and human epididymis protein 4 (HE4)] in the diagnosis of epithelial OC (EOC). METHODS This is a case-control study that included fifty females diagnosed with EOC, 10 females with benign ovarian masses recruited from the Egyptian National Cancer Institute, and 30 healthy females as a control group. All subjects were assessed for serum HE4, CA125, IGFBP2, TSP1 and SPP1 measurement by enzyme-linkedimmunosorbent assay. RESULTS There was a statistically significant difference in serum levels between EOC, benign ovarian masses, and healthy control groups regarding CA125 and SPP1 (P < 0.001 for both markers), while HE4 and IGFBP2 increased significantly in EOC compared to healthy control groups (P < 0.001 for all markers) with no significant difference between EOC and benign ovarian masses groups. However, there was no statistically significant difference among EOC, benign ovarian masses, and healthy control groups regarding the TSP1 serum levels (P = 0.051). Receiver operating characteristic analysis revealed that combined assessment of SPP1 with CA125 or TSP1 increased the diagnosis of EOC patients to a sensitivity, specificity, and area under curve of (93.3%, 100%, 0.968; respectively, P < 0.001). CONCLUSION SPP1 may be a potential marker for the differentiation between benign and malignant ovarian masses, while IGFBP2 can differentiate between healthy females and females with ovarian masses. Combining SPP1 with CA125 or TSP1 provides high sensitivity and specificity for the detection of EOC patients.Keywords
This publication has 60 references indexed in Scilit:
- Osteopontin in cancer2024
- Novel Association of IGF2BP2 Gene Variants With Altered Risk of Breast Cancer and as Potential Molecular Biomarker of Triple Negative Breast CancerClinical Breast Cancer, 2022
- Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian TumorsBulletin of Experimental Biology and Medicine, 2016
- Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysisTumor Biology, 2014
- Thrombospondins: from structure to therapeuticsCellular and Molecular Life Sciences, 2008
- Osteopontin as a Potential Diagnostic Biomarker for Ovarian CancerJAMA, 2002
- Thrombospondin-1 Expression in Epithelial Ovarian Carcinoma: Association with p53 Status, Tumor Angiogenesis, and Survival in Platinum-Treated PatientsGynecologic Oncology, 2001
- Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel densityVirchows Archiv, 2001
- Plasma thrombospondin levels in patients with colorectal carcinomaCancer, 1998